The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion
Jamilah R. George, Timothy I. Michaels, Jae Sevelius, Monnica T. Williams
Journal of Psychedelic Studies July 1, 2019 DOI: 10.1556/2054.2019.015 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Indigenous Mainstream Ethnic group Inclusion mineral Narrative White mutation Sociocultural evolution The renaissance Historical trauma Gender studies Psychotherapist Anthropology |
| Citations | 222 |
| Key findings | The mainstream narrative of psychedelic medicine often fails to acknowledge the contributions of indigenous people, ethnic and racial minorities, women, and other disenfranchised groups, and a more inclusive cultural focus is needed. |
Abstract
In recent years, the study of psychedelic science has resurfaced as scientists and therapists are again exploring its potential to treat an array of psychiatric conditions, such as depression, post-traumatic stress disorder, and addiction. The scientific progress and clinical promise of this movement owes much of its success to the history of indigenous healing practices; yet the work of indigenous people, ethnic and racial minorities, women, and other disenfranchised groups is often not supported or highlighted in the mainstream narrative of psychedelic medicine. This review addresses this issue directly: first, by highlighting the traditional role of psychedelic plants and briefly summarizing the history of psychedelic medicine; second, through exploring the historical and sociocultural factors that have contributed to unequal research participation and treatment, thereby limiting the opportunities for minorities who ought to be acknowledged for their contributions. Finally, this review provides recommendations for broadening the Western medical framework of healing to include a cultural focus and additional considerations for an inclusive approach to treatment development and dissemination for future studies.
Citations in the library
Cited by 190
- Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer Journal of Psychopharmacology January 9, 2020
- Long-term effects of psychedelic drugs: A systematic review Neuroscience & Biobehavioral Reviews March 16, 2020
- Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature BMC Psychiatry July 31, 2018
- Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression Frontiers in Pharmacology March 31, 2022
- Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness. Frontiers in Pharmacology March 25, 2021
and 185 more in the library
Cites 34
- Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans Archives of General Psychiatry March 1, 1994
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
and 29 more in the library